CoChat
Sign Up
Cited by 331Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug ReactionsImmunotherapy and Immune Responses

The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Stroud, Chipman RG, Hegde, Aparna, Cherry, Cynthia, Naqash, Abdul R, Sharma, Nitika, Addepalli, Srikala, Cherukuri, Sulochana, Parent, Teresa, Hardin, Jessica, Walker, Paul·2019·Journal of Oncology Pharmacy Practice
DOI 10.1177/1078155217745144
Open this paper in CoChat — free account

Abstract

BACKGROUND: Immune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited to single center experiences. Our initial experience with the IL-6 receptor antagonist tocilizumab showed clinical improvement in a wide variety of irAEs. As a result, we adopted the use of tocilizumab for the management of steroid refractory irAEs. METHODS: The character and clinical course of irAEs were abstracted from the medical record and analyzed. The dose of tocilizumab was 4 mg/kg given IV over one hour. C-reactive protein was drawn at first nivolumab infusion and at q two weeks (and with irAEs) thereafter. Clinical improvement was defined as either: documentation of resolution of symptoms or hospital discharge within seven days. RESULTS: Of the initial 87 patients that were treated with nivolumab, 34 required tocilizumab (39.1%). All patients were on corticosteroids. The majority (88.2%) were lung cancer patients. The index grade 3/4 irAE was pneumonitis in 35.3%, serum sickness/SIRS in 35.3%, cerebritis in 14.7% and one case each of hypophysitis, colitis, pancreatitis, hepatitis and immune mediated coagulopathy. Median time between first nivolumab and initiation of tocilizumab was 76 days (range 1-429). There was a statistically significant increase in C-reactive protein from a median of 23 mg/L (range 0.1-238.5) at baseline to 109.3 mg/L (21.5-350.4) at the time of index irAE, followed by a decrease to 19.2 mg/L (0.25-149) after tocilizumab ( p < 0.00001). Clinical improvement was noted in 27/34 patients (79.4%). Some patients (52.9%) required a single dose, while 38.2% required two, 8.8% required three and 1 patient required four doses. Twenty-seven doses were given in the inpatient setting (49.1%). Median time to discharge was four days (range 1-27). Seventy-four percent of patients were discharged home. For the 53 doses of tocilizumab that were delivered when infliximab was an option, there was a cost savings of $141,048.72 (WAC) during the 18 month study period. CONCLUSIONS: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade. However, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.

Overview

Integrity signals

Registry

Crossref · 10.1177/1078155217745144

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Haratani K, JAMA Oncol
  2. Shoushtari AN, JAMA Oncol
  3. 10.1093/annonc/mdv623 · DOI · Paper page
  4. Kim N, 2015, Oncology Letters, 9

Cited by

Sorted by citations

See all 331

Related

See all

Metadata

Authors
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P.
Affiliations
East Carolina University (US)
Corresponding author
Hegde, Aparna
ORCID
Venue
Journal of Oncology Pharmacy Practice
Publisher
SAGE Publications
Published
2017-12-05
Volume
25
Issue
3
Pages
551-557
ISSN
  • 1078-1552 (ISSN-L)
  • 1477-092X
DOI
10.1177/1078155217745144
OpenAlex
W2771433910
Cited by
331
References
26
Citations by year
2026: 25 · 2025: 28 · 2024: 43 · 2023: 45 · 2022: 55 · 2021: 46 · 2020: 58 · 2019: 22 · 2018: 7 · 2017: 1
FWCI
10.61
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Oncology Pharmacy Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tocilizumab, immune checkpoint inhibitors, immune-related adverse events, nivolumab, IL-6 receptor inhibitor, pneumonitis, serum sickness, C-reactive protein, lung cancer, hypophysitis, colitis, cerebritis, hypotension, hypoxemia
MeSH terms
Nivolumab, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review